Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

IMCUSTOMEYE

Financiado

IMaging based CUSTOMised EYE diagnostics

Prevalent eye diseases, such as glaucoma, keratoconus, refractive errors, cataract, myopia and presbyopia, affect millions worldwide, and only in Europe represent over €20 billion annual cost to society. Current screening tools re... ver más

31/12/2022

CSIC

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Ver 11 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ICT-30-2017: Photonics KET 2017

I+D

Cerrada hace 7 años

0% 100%

11 Participantes

CSIC

1.81M€ | Lider

Iroc Science AG

481.30K€ | Participante

IChF PAN

1.07M€ | Participante

2EYES VISION

186.17K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 60 meses Fecha Inicio: 2017-12-20
Fecha Fin: 2022-12-31

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA...

TRL 2-3 | 552M€

Presupuesto del proyecto 6M€

Descripción del proyecto Prevalent eye diseases, such as glaucoma, keratoconus, refractive errors, cataract, myopia and presbyopia, affect millions worldwide, and only in Europe represent over €20 billion annual cost to society. Current screening tools rely on morphological biomarkers based on corneal shape and optics, yet differences in biomechanical properties underlie and precede disease development (i.e. keratoconus, ectasia risk) or affect standard markers (i.e. intraocular pressure in glaucoma). IMCUSTOMEYE will develop new diagnostic paradigms for these vision-threatening conditions, with a direct impact on their treatment. We will deploy new compact, easy-to-use, label-free non-invasive imaging-based instrumentation for direct measurement of corneal biomechanical properties in patients. The technology is based on imaging concepts brought from other disciplines into ophthalmology and, for the first time, applied in patients in vivo. Dynamic corneal imaging based on air-puff stimulated Optical Coherence Tomography corneal deformation and acoustic stimulated phase sensitive and nanosensitive Optical Coherence Tomography corneal vibrography will be coupled to corneal mechanical models to estimate corneal elasticity and viscoelasticity parameters (isolated from other factors). Corneal biomechanical properties will be used as biomarkers for in-depth diagnosis of keratoconus and ectasia risk, and to provide accurate estimates of intraocular pressure in glaucoma diagnosis. Clinical validations in ophthalmology hospitals will demonstrate the diagnostic and treatment predictive potential of the customised optical and biomechanical eye models from patient-specific enabled by the new technology. IMCUSTOMEYE will contribute to more effective, customised treatment of eye diseases and to reinforce industrial leadership in the area of diagnostic imaging in ophthalmology.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores